Clearly, data for anti-PD-1 plus the anti-LAG-3, relatlimab, are also promising, with significantly improved PFS for relatlimab with nivolumab versus nivolumab alone from the RELATIVITY-047 phase III trial of 714 patients with advanced melanoma [39]. Here, RPL17 is linked to melanoma.